His Royal Highness Prince Salman bin Hamad Al Khalifa, the Crown Prince and Prime Minister, today met with the Chairman of China National Pharmaceutical Group Corporation (Sinopharm), Liu Jingzhen, at Gudaibiya Palace.
His Royal Highness highlighted the importance of internationally coordinated efforts to meet global health challenges, noting the Kingdom’s commitment to supporting initiatives to safeguard global health security.
His Royal Highness commended the existing cooperation between the Kingdom of Bahrain and Sinopharm in healthcare, as part of the ongoing efforts to to serve humanity and ensure the health and safety of all.
His Royal Highness also expressed appreciation for the cooperation between Bahrain and Sinopharm, highlighting the Kingdom’s participation in phase-III anti-virus clinical trials in cooperation with Abu Dhabi-based artificial intelligence and Cloud Computing company, Group 42 (G42), which were conducted in the United Arab Emirates and the People’s Republic of China.
His Royal Highness reiterated Bahrain’s commitment to furthering coordination with relevant authorities and companies in the healthcare and treatment sector to achieve common aspirations.
For his part, the Chairman of Sinopharm expressed his appreciation for His Royal Highness’ support of international cooperation in health affairs.
The Chairman also thanked the Kingdom of Bahrain for its constructive cooperation in promoting the health and greater good of and wished Bahrain further progress and prosperity.
The Minister of Finance and National Economy, HE Shaikh Salman bin Khalifa Al Khalifa, and the Minister of Cabinet Affairs, HE Hamad bin Faisal Al Malki, also attended the meeting.